GlySure Aims For ICU Continuous Glucose Monitor Trial This Year
This article was originally published in The Gray Sheet
Executive Summary
GlySure hopes to begin a multi-center clinical trial in the U.S. and Europe by year-end for its continuous intravascular glucose monitoring system designed for use with intensive-care-unit patients.
You may also be interested in...
FDA Wants To See New, Improved Hospital Continuous Glucose Monitors
FDA is encouraging industry to submit study designs for newer, more accurate continuous glucose monitors for hospital use. It gathered experts at a June 25 public meeting to discuss questions around indications for use and trial designs.
Financings In Brief
Aria Diagnostics and Gene Security Network/Natera raise funds for non-invasive prenatal test development. More financings.
FDA Holds Up Edwards-DexCom Continuous Glucose Monitor For Hospital Use
Edwards Lifesciences' and DexComs’ first-of-its-kind continuous glucose monitor for hospital use is running into delays at FDA.